Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"We are extremely pleased to enter this strategic licensing agreement, our first major deal leveraging our pioneering Dark Antigen discovery and validation capabilities," said Kevin Pojasek, President and CEO of Enara Bio. "Boehringer Ingelheim is an innovation-led company dedicated to producing breakthrough treatments with a significant focus on cancer. We are excited to build this relationship and are encouraged that Boehringer Ingelheim shares our view of the potential of Dark Antigens to be a source of important and unconventional targets for novel cancer immunotherapies. This agreement provides strong validation for our science and our approach to exploiting the cancer-associated antigenic repertoire derived from genomic dark matter and we look forward to a productive collaboration."
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
INGELHEIM, Germany & OXFORD, England & LONDON -- Businesswire -- Boehringer Ingelheim and Enara Bio, today announced that they have entered into a strategic collaboration and licensing agreement to research and develop novel targeted cancer immunotherapies, leveraging Enara Bio’s Dark Antigen™ discovery platform. This new collaboration combines Boehringer Ingelheim’s approach to tackle cancer through pairing leading science with innovative immune-oncology platforms, such as oncolytic viruses and cancer vaccines, with Enara Bio’s expertise in cancer antigen identification. The aim is to provide potential new therapies for patients with difficult to treat lung and gastrointestinal cancers.
“We are excited to partner with Enara Bio as part of our mission to bring transformative new treatments to cancer patients,” said Jonathon Sedgwick, Ph.D., Senior Vice President and Global Head, Cancer Immunology & Immune Modulation Research, Boehringer Ingelheim. “We are advancing a unique pipeline of cancer cell-directed agents, immuno-oncology therapies and intelligent combination approaches to help combat cancer. Enara Bio’s unique discovery platform offers a novel and highly differentiated approach that will allow us to look beyond the known proteome to identify and characterize Dark Antigens to support the development of T-Cell Receptor (TCR)-directed immunotherapies and therapeutic vaccines. We believe this is a highly innovative and promising approach to the development of the next wave of cancer immunotherapies.”
Enara Bio’s proprietary Dark Antigen Platform Technology (EDAPT™) will be used to discover and validate novel Dark Antigens in up to three tumor types in the lung and gastrointestinal cancer space. The discovery of shared antigens could lead to the development of vaccines that can be readily utilized to help a broader group of cancer patients.
Dark Antigens represent a new class of cancer-associated antigens that derive from the genomic dark matter, or the portion of the human genome that is normally not expressed as protein. Dark Antigen-encoding sequences are usually silenced in healthy cells but are activated and presented on tumor cells. They are associated with specific cancer types and, importantly, are shared across patients. Since typically not visible to the immune system, they represent a large potential repertoire of novel antigens that can be developed as targets for new immunotherapies.
“We are extremely pleased to enter this strategic licensing agreement, our first major deal leveraging our pioneering Dark Antigen discovery and validation capabilities,” said Kevin Pojasek, President and CEO of Enara Bio. “Boehringer Ingelheim is an innovation-led company dedicated to producing breakthrough treatments with a significant focus on cancer. We are excited to build this relationship and are encouraged that Boehringer Ingelheim shares our view of the potential of Dark Antigens to be a source of important and unconventional targets for novel cancer immunotherapies. This agreement provides strong validation for our science and our approach to exploiting the cancer-associated antigenic repertoire derived from genomic dark matter and we look forward to a productive collaboration.”
This collaboration with Enara Bio is the latest of several strategic partnerships and acquisitions for Boehringer Ingelheim to build its cancer vaccine platform and provides important validation for Enara Bio’s Dark Antigen platform. The past acquisitions of ViraTherapeutics and AMAL Therapeutics’ vaccine modalities coupled with Enara Bio’s capabilities position Boehringer Ingelheim to develop sophisticated virus and vaccine modalities for its prime/boost vaccine platform.
Under the agreement, Boehringer Ingelheim has the option to license Dark Antigens discovered and validated by Enara Bio. Boehringer Ingelheim will also be responsible for all non-clinical and clinical development, as well as commercialization of associated cancer immunotherapies, including therapeutic vaccines and T-cell redirecting biologics. Enara Bio retains rights to use any discovered antigens for use in cell therapy-based products.
Enara Bio is eligible to receive an upfront payment, together with research/preclinical milestones and licensing fees for each tumor type that is explored. Enara Bio is also eligible to receive more than EUR 876 million in clinical, regulatory and commercial milestones, in addition to royalties on future product sales.
Please click on the following link for ‘Notes to Editors’: http://www.boehringer-ingelheim.com/press-release/strategic-collaboration-enarabio
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005444/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Boehringer Ingelheim International GmbH
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 현대자동차, 북미서 수소전기트럭 사업 본격 전개 - 뉴스와이어
- 클린 바디케어 브랜드 데미플로, 첫 전속모델로 배우 ‘이이담’ 발탁 - 뉴스와이어
- 대한항공, 포르투갈 리스본 직항 노선 운항 - 뉴스와이어
- 보쉬 모빌리티 애프터마켓 사업부, 황사와 미세먼지 많은 봄철 내 차에 맞는 에어컨/히터 필터
- LG생활건강 숨37°, 첫 단계 슬로우에이징 ‘시크릿 에센스’ 4세대 출시 - 뉴스와이어
- 동국제강, 환경성적표지 국제 인증 취득 - 뉴스와이어
- 구조견 ‘줄기세포 치료’로 다리 마비 극복… 반려견 치료 새 장 열리나 - 뉴스와이어
- 세스코, 키자니아에 어린이 가상현실 직업체험관 오픈 - 뉴스와이어
- 팍스젠바이오, 중소벤처기업부 주관 ‘글로벌강소기업 1000+ 프로젝트’ 최종 선정 - 뉴스와이어
- 에덴요양병원, 고속도로 개통으로 접근성 크게 개선 - 뉴스와이어